Dr. Chlebowski on Dietary Modifications in Patients With Breast Cancer

Video

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California, Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses a planned follow-up analysis of the Women's Health Initiative Dietary Modification study, which examined the impact of reduced dietary fat intake in patients with breast cancer.

The Dietary Modification study monitored dietary fat intake but not weight loss, Chlebowski explains, though there was a statistically significant amount of weight loss reported. After 8 years of intervention, data showed 9% fewer breast cancers, with a hazard ratio of .91, out of 1700 cases.

A second planned follow-up analysis that will examine survival of patients who participated in the Dietary Modification study. Researchers may be able to determine if dietary modifications had an influence on tumor growth characteristics. However, Chlebowski notes that body mass index and physical activity are shown to have greater significance on this factor.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute